Mizuho raised the firm’s price target on Axsome Therapeutics to $112 from $90 and keeps a Buy rating on the shares. Ahead of Q4 earnings, the firm updated models and revised 12-month price targets in the biotechnology space.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AXSM:
- TipRanks’ ‘Perfect 10’ List: These 3 Top-Scoring Stocks Tick All the Right Boxes
- Biotech Alert: Searches spiking for these stocks today
- Tesla downgraded, UPS upgraded: Wall Street’s top analyst calls
- Axsome Therapeutics initiated with a Buy at UBS
- Tesla, Boeing downgraded: Wall Street’s top analyst calls